C81.27 Mixed cellularity Hodgkin lymphoma, spleen

Name of the Condition

• Mixed Cellularity Hodgkin Lymphoma, Spleen (ICD-10: C81.27)

Summary

Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma characterized by a heterogeneous mix of cell types within affected lymph nodes. It is one of the classical Hodgkin lymphoma subtypes, distinguished by the presence of Reed-Sternberg cells and a variable inflammatory background. This subtype typically presents with widespread lymph node involvement and may affect other lymphoid tissues or organs. The "spleen" designation specifies the anatomical location of the lymphoma.

Causes

The exact cause of mixed cellularity Hodgkin lymphoma is not fully understood, but it is associated with genetic mutations and immune system dysregulation. Epstein-Barr virus (EBV) infection is frequently linked to this subtype, suggesting a potential role in its development. Other contributing factors may include genetic predisposition and environmental exposures, though specific triggers remain under investigation.

Risk Factors

• Age: Most common in adults, with a peak incidence in the 30-50 age range.
• Gender: Slightly more prevalent in males.
• Epstein-Barr virus infection: Prior exposure increases risk.
• Immune system suppression: Conditions like HIV/AIDS or immunosuppressive therapy may elevate susceptibility.
• Family history: A first-degree relative with lymphoma may increase risk.

Symptoms

• Painless swelling of lymph nodes, often in the neck, armpits, or groin
• Fever, night sweats, or unexplained weight loss
• Fatigue or weakness
• Loss of appetite
• Enlarged spleen (splenomegaly) may cause abdominal discomfort or fullness

Diagnosis

Diagnosis typically involves a combination of physical examination, imaging studies (e.g., CT scans or PET scans), and biopsy of affected tissue. A lymph node or spleen biopsy is essential to identify Reed-Sternberg cells and confirm the subtype. Blood tests may also be performed to assess overall health and detect abnormalities. Staging helps determine the extent of the disease and guide treatment.

Treatment Options

Treatment depends on the stage and location of the lymphoma. Common approaches include chemotherapy, often combined with immunotherapy (e.g., monoclonal antibodies). Radiation therapy may be used for localized disease. Stem cell transplantation is an option for advanced or recurrent cases. Treatment plans are individualized based on the patient’s overall health and response to therapy.

Prognosis and Follow-Up

The prognosis for mixed cellularity Hodgkin lymphoma is generally favorable, especially when diagnosed early. Most patients respond well to treatment, with many achieving long-term remission. Follow-up care includes regular monitoring for recurrence, which may involve imaging, blood tests, or physical exams. Long-term survivors may require ongoing surveillance for late effects of treatment.

Complications

• Recurrence of lymphoma
• Infection due to weakened immune system
• Secondary cancers from treatment (e.g., radiation or chemotherapy)
• Organ damage (e.g., from enlarged spleen or treatment side effects)

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid smoking and limit alcohol consumption.
• Practice good hygiene to reduce infection risk.
• Stay up-to-date with vaccinations, as recommended by a healthcare provider.
• Manage stress through relaxation techniques or support groups.

When to Seek Professional Help

Seek medical attention if you experience persistent lymph node swelling, unexplained weight loss, fever, or fatigue. Early evaluation is important for timely diagnosis and treatment. Contact a healthcare provider immediately if symptoms worsen or new concerning signs appear.

Tips for Medical Coders

When coding for mixed cellularity Hodgkin lymphoma of the spleen (C81.27), ensure the diagnosis is clearly documented in the medical record. Verify that the anatomical site (spleen) is explicitly stated to support the code assignment. Review clinical notes for confirmation of the subtype and any associated conditions that may impact coding accuracy. Document any relevant staging or treatment details to support comprehensive coding.